Ghana

Ghana Health Service Ethical Review Committee

Ghana Health Service

Research and Development Division

Chairperson
Dr John Gyapong (John.Gyapong@hru-ghs.org)

Organisation administrator's name or contact person
Dr Hannah Frimpong (Hannah.Frimpong@hru-ghs.org)

Telephone number: 233 021 681109

Fax Number:

Physical address
Ghana Health Service Ethical Review Research and Development Division Ghana Health Service Adabraka Polyclinic Opposite Accra Psychiatric Hospital Cathedral Square Castle Road Accra

Postal address
Ghana Health Service Ethical Review Committee Research and Development Division P. O. Box MB 190 Accra. Ghana Health Service Ethical Review Committee Accra Ghana

Country
Ghana

Institution website address
http://www.ghanahealthservice.org/division.php?dsion=Research and Development&dd=35

Organisation Info.

What is the institutional affilliation of your Organisation
Government

Level of operation

What is the level of operation
Institutional

Protocols Submission Information

What is your preferred manner to receive protocols
All the above

What is the operational language(s) of the organisation
English

How often does your organisation convene to consider study protocols
every two months

How long in advance should the protocol be submitted to be considered at the next meeting
1 month

If you have a timetable, please provide this information here
The members of the committee meet every two months to review and take decisions on research protocols. In addition, a four member sub-committee is put in place during recess of the Committee, to carry out expedited reviews of protocols.

If there is any other organisation information you wish to appear on the website, please complete this here
Requirements for ethical approval: • Scientific Review approval • Overall Study design • Methodology • Sampling and Sample size i.e. selection processes/ inclusion and exclusion criteria • Procedures and arrangement for Referral Services/Basic level of follow up care and Medical support for Adverse Effects (if study is invasive/ clinical trial) • Arrangement for follow ups (if study is invasive/clinical trial) • Food and Drugs Boards approval letter Investigational Product • Material Transfer Agreement • Profile of Data Safety Monitoring Board (DSMB) and their charter of work • Ethical Considerations (risks & benefits) • Insurance Cover for participants • Budget • Sponsors • Investigational Brochure for investigations products • Collaborators CVs and Institutional letter

Details of Members

Is this term renewable
Not renewable